TAK Latest Press Releases

-- October 23, 2026 --

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Business Wire 7:30 AM

-- October 19, 2026 --

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO (vedolizumab) Prolongs Time to First Disease-Related Complication Business Wire 5:30 AM

-- October 14, 2026 --

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 Business Wire 8:30 PM

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 Business Wire 8:00 AM

-- September 30, 2026 --

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill Business Wire 1:00 AM

-- September 22, 2026 --

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 Business Wire 9:30 AM

-- September 18, 2026 --

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems Business Wire 1:00 AM

-- September 14, 2026 --

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations Business Wire 3:00 AM

-- September 9, 2026 --

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life Business Wire 8:24 AM

-- August 28, 2026 --

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Business Wire 6:40 PM

-- August 24, 2026 --

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire 2:36 AM

-- August 5, 2026 --

U.S. FDA Approves Takeda's ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire 6:10 PM

-- July 30, 2026 --

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track Business Wire 2:37 AM

-- July 16, 2026 --

Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies Business Wire 6:00 PM

-- July 12, 2026 --

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products Business Wire 7:00 PM

-- June 24, 2026 --

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO Business Wire 3:05 AM

-- June 23, 2026 --

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations PRNewswire 8:00 AM

-- June 15, 2026 --

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 Business Wire 12:00 PM

-- June 11, 2026 --

Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire 7:00 AM

-- June 9, 2026 --

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease Business Wire 4:30 PM

Market Data Delayed 15 Minutes